Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists.

Two distinct G protein-coupled purinergic receptors, P2Y1 and P2Y12, mediate ADP-driven platelet activation. The clinical effectiveness of P2Y12 blockade is well established. Recent preclinical data suggest that P2Y1 and P2Y12 inhibition provide equivalent antithrombotic efficacy, while targeting P2Y1 has the potential for reduced bleeding liability. In this account, the discovery of a 2-(phenoxypyridine)-3-phenylurea chemotype that inhibited ADP-mediated platelet aggregation in human blood samples is described. Optimization of this series led to the identification of compound 16, 1-(2-(2-tert-butylphenoxy)pyridin-3-yl)-3-4-(trifluoromethoxy)phenylurea, which demonstrated a 68 ± 7% thrombus weight reduction in an established rat arterial thrombosis model (10 mg/kg plus 10 mg/kg/h) while only prolonging cuticle and mesenteric bleeding times by 3.3- and 3.1-fold, respectively, in provoked rat bleeding time models. These results suggest that a P2Y1 antagonist could potentially provide a safe and efficacious antithrombotic profile.

[1]  K. Jacobson,et al.  Molecular Structure of P2Y Receptors: Mutagenesis, Modeling, and Chemical Probes. , 2012, Wiley interdisciplinary reviews. Membrane transport and signaling.

[2]  K. Jacobson,et al.  Virtual screening leads to the discovery of novel non-nucleotide P2Y₁ receptor antagonists. , 2012, Bioorganic & medicinal chemistry.

[3]  Colin W. Taylor,et al.  P2Y receptor subtypes evoke different Ca2+ signals in cultured aortic smooth muscle cells , 2012, Purinergic Signalling.

[4]  Dwight M. Morrow,et al.  Benzofuran-substituted urea derivatives as novel P2Y(1) receptor antagonists. , 2010, Bioorganic & medicinal chemistry letters.

[5]  K. Jacobson,et al.  P2Y nucleotide receptors: promise of therapeutic applications. , 2010, Drug discovery today.

[6]  M. Cattaneo.  New P2Y12 Inhibitors , 2010, Circulation.

[7]  H. Zachrisson,et al.  Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. , 2009, Thrombosis research.

[8]  Dwight M. Morrow,et al.  Tetrahydro-4-quinolinamines identified as novel P2Y(1) receptor antagonists. , 2008, Bioorganic & medicinal chemistry letters.

[9]  J. Hirsh,et al.  Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future , 2008, Nature Clinical Practice Cardiovascular Medicine.

[10]  G. Lu,et al.  P2Y1 receptor antagonists as novel antithrombotic agents. , 2008, Bioorganic & medicinal chemistry letters.

[11]  L. Wallentin,et al.  Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. , 2007, Cardiovascular drug reviews.

[12]  P. Leeson,et al.  From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. , 2007, Bioorganic & medicinal chemistry letters.

[13]  R. Rehfuss,et al.  Biomarker Optimization to Track the Antithrombotic and Hemostatic Effects of Clopidogrel in Rats , 2007, Journal of Pharmacology and Experimental Therapeutics.

[14]  Eric A. Barnard,et al.  International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy , 2006, Pharmacological Reviews.

[15]  P. Sandset,et al.  Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. , 2006, European heart journal.

[16]  A. Siegbahn,et al.  Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. , 2006, European heart journal.

[17]  K. Jacobson,et al.  Positive Inotropic Effects by Uridine Triphosphate (UTP) and Uridine Diphosphate (UDP) via P2Y2 and P2Y6 Receptors on Cardiomyocytes and Release of UTP in Man During Myocardial Infarction , 2006, Circulation research.

[18]  G. Reiser,et al.  Diadenosine and diuridine poly(borano)phosphate analogues: synthesis, chemical and enzymatic stability, and activity at P2Y1 and P2Y2 receptors. , 2006, Journal of medicinal chemistry.

[19]  Kenneth A Jacobson,et al.  Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. , 2003, Journal of medicinal chemistry.

[20]  M. Maftouh,et al.  Structure and stereochemistry of the active metabolite of clopidogrel. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[21]  G. Reiser,et al.  Adenosine 5'-O-(1-boranotriphosphate) derivatives as novel P2Y(1) receptor agonists. , 2002, Journal of medicinal chemistry.

[22]  K. Jacobson,et al.  Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking. , 2001, Journal of medicinal chemistry.

[23]  M. Freund,et al.  Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. , 2001, Circulation.

[24]  David Julius,et al.  Identification of the platelet ADP receptor targeted by antithrombotic drugs , 2001, Nature.

[25]  J. Boeynaems,et al.  Overview of P2Y receptors as therapeutic targets , 2001 .

[26]  G. Burnstock,et al.  P2 purinergic receptors: modulation of cell function and therapeutic potential. , 2000, The Journal of pharmacology and experimental therapeutics.

[27]  S. Moro,et al.  Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. , 2000, Journal of medicinal chemistry.

[28]  A. Bailey,et al.  Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. , 1999, Journal of medicinal chemistry.

[29]  K. Jacobson,et al.  Competitive and selective antagonism of P2Y1 receptors by N6‐methyl 2′‐deoxyadenosine 3′,5′‐bisphosphate , 1998, British journal of pharmacology.

[30]  K. Jacobson,et al.  Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors. , 1998, Journal of medicinal chemistry.

[31]  S. Sigurdsson,et al.  A Mild and Simple Method for the Preparation of Isocyanates from Aliphatic Amines Using Trichloromethyl Chloroformate. Synthesis of an Isocyanate Containing an Activated Disulfide. , 1996, The Journal of organic chemistry.

[32]  M. Parmentier,et al.  Cloning and tissue distribution of the human P2Y1 receptor. , 1996, Biochemical and biophysical research communications.

[33]  P. Leff,et al.  FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T‐purinoceptors , 1994, British journal of pharmacology.

[34]  G. Burnstock,et al.  Purinoceptors: are there families of P2X and P2Y purinoceptors? , 1994, Pharmacology & therapeutics.